The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer.

PURPOSE To identify groups of early breast cancer patients with substantial risk (10-year risk > 20%) for locoregional failure (LRF) who might benefit from postmastectomy radiotherapy (RT). PATIENTS AND METHODS Prognostic factors for LRF were evaluated among 6,660 patients (2,588 node-negative patients, 4,072 node-positive patients) in International Breast Cancer Study Group Trials I to IX treated with chemotherapy and/or endocrine therapy, and observed for a median of 14 years. In total, 1,251 LRFs were detected. All patients were treated with mastectomy without RT. RESULTS No group with 10-year LRF risk exceeding 20% was found among patients with node-negative disease. Among patients with node-positive breast cancer, increasing numbers of uninvolved nodes were significantly associated with decreased risk of LRF, even after adjustment for other prognostic factors. The highest quartile of uninvolved nodes was compared with the lowest quartile. Among premenopausal patients, LRF risk was decreased by 35% (P = .0010); among postmenopausal patients, LRF risk was decreased by 46% (P < .0001). The 10-year cumulative incidence of LRF was 20% among patients with one to three involved lymph nodes and fewer than 10 uninvolved nodes. Age younger than 40 years and vessel invasion were also associated significantly with increased risk. Among patients with node-positive disease, overall survival was significantly greater in those with higher numbers of uninvolved nodes examined (P < .0001). CONCLUSION Patients with one to three involved nodes and a low number of uninvolved nodes, vessel invasion, or young age have an increased risk of LRF and may be candidates for a similar treatment as those with at least four lymph node metastases.

[1]  C. Grau,et al.  Loco-regional recurrence after mastectomy in high-risk breast cancer--risk and prognosis. An analysis of patients from the DBCG 82 b&c randomization trials. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[2]  R. Collins,et al.  Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[3]  R. Gelber,et al.  Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  J. Kao,et al.  Does the number of lymph nodes examined in patients with lymph node‐negative breast carcinoma have prognostic significance? , 2005, Cancer.

[5]  A. Taghian,et al.  Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Satagopan,et al.  A note on competing risks in survival data analysis , 2004, British Journal of Cancer.

[7]  M. Bonetti,et al.  Patterns of treatment effects in subsets of patients in clinical trials. , 2004, Biostatistics.

[8]  M. Bonetti,et al.  Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. , 2003, Journal of the National Cancer Institute.

[9]  H. Putter,et al.  Impact of locoregional treatment on the early-stage breast cancer patients: a retrospective analysis. , 2003, European journal of cancer.

[10]  P. Catalano,et al.  Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Forbes,et al.  Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII. , 2003, Journal of Clinical Oncology.

[12]  E. Yıldırım,et al.  The prognostic significance of total lymph node number in patients with axillary lymph node-negative breast cancer. , 2003, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[13]  G. Storme,et al.  Effect of the number of uninvolved nodes on survival in early breast cancer. , 2003, Oncology reports.

[14]  M. Bonetti,et al.  Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial. , 2002, Journal of the National Cancer Institute.

[15]  L. Holmberg,et al.  Five-node biopsy of the axilla: an alternative to axillary dissection of levels I-II in operable breast cancer. , 2002, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[16]  J. Peterse,et al.  Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  S. Edge,et al.  Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  B. Nordenskjöld,et al.  Indicators of loco-regional recurrence in breast cancer. The South East Swedish Breast Cancer Group. , 2000, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[19]  R. Gelber,et al.  Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? , 2000, The Lancet.

[20]  R. Prescott,et al.  Management of the axilla in operable breast cancer treated by breast conservation: a randomized clinical trial , 2000, The British journal of surgery.

[21]  R. Gray,et al.  Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[23]  B. Rasmussen,et al.  Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial , 1999, The Lancet.

[24]  R. Gelber,et al.  Radiotherapy and chemotherapy in high-risk breast cancer. , 1998, The New England journal of medicine.

[25]  K. Zedeler,et al.  Postoperative Radiotherapy in High-Risk Premenopausal Women with Breast Cancer Who Receive Adjuvant Chemotherapy , 1997 .

[26]  J. Forbes,et al.  The International (Ludwig) Breast Cancer Study Group Trials I-IV: 15 years follow-up. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  A. Goldhirsch,et al.  Prognostic significance of peritumoral vessel invasion in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. , 1985, Human pathology.

[28]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .

[29]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[30]  I. Fentiman,et al.  A high number of tumor free axillary lymph nodes from patients with lymph node negative breast carcinoma is associated with poor outcome , 2002, Cancer.

[31]  M. Zelen,et al.  Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  S. Green,et al.  Adjuvant CMFVP versus adjuvant CMFVP plus ovariectomy for premenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  M. Zelen,et al.  Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. , 1989, The New England journal of medicine.